Study: Testing All Adults for Hepatitis C Virus is Cost-Effective

Public health organizations have long been urging baby boomers at get tested for hepatitis C virus (HCV), as this population is historically considered the most at-risk for the infection. However, an increase in HCV rates among younger injection drug users has caused a gap in testing that could leave this population at risk for chronic infection and organ damage that will lead to higher medical costs down the line.
A study published by Clinical Infectious Diseases suggests that screening all adults for HCV may be cost-effective and could also identify more patients with the infection than current recommendations.
To address the disparities in testing rates, the study authors developed simulations to determine the efficacy of HCV testing strategies among different age groups. Data from databases, clinical trials, and observational cohorts were included in the study.
Specifically, the researchers looked at current recommendations for testing individuals over 30 years of age or those over 40 years of age, and testing all adults over 18 years. Both approaches also targeted high-risk individuals, according to the authors.
The results suggest that testing all adults would lead to 250,000 more HCV diagnoses and increase cure rates from 41% to 61%, according to the study.
Additionally, widespread testing would also reduce the risk of death from HCV-linked conditions by more than 20% compared with current guidelines.
“When we expanded testing, the results were compelling,” said lead author Joshua Barocas, MD. “Changing the current recommendations could have a major public health impact, improving the quality of life for young people with HCV, and reducing death rates.”
Although age-based strategies reduced costs associated with managing HCV and associated liver disease, the authors discovered that testing all adults was the most cost-effective approach overall.
The cost benefit of the testing-all-adults strategy remained true even in a simulation that required double the amount of testing to achieve the same number of diagnoses, according to the study.
“Testing all adults would lead to earlier diagnosis and treatment for many people, which would help to prevent cirrhosis and other long-term complications,” said senior author Joshua Salomon, PhD. “Overall, when you consider both the better health outcomes and the reduced costs of managing long-term liver disease, expanded testing offers excellent value for money.”
Due to the severity of the opioid epidemic, more Americans are contracting HCV and other blood borne diseases. Despite the seriousness of these conditions, current guidelines may only target traditional risk populations and not injection drug users.
The authors said that these findings could be used by the CDC to guide future HCV testing guidelines.
“Due in part to the opioid epidemic and the increase in injection drug use, the country has seen an increase in cases of HCV among young people,” said co-senior author Benjamin Linas, MD. “The CDC could address this public health concern by recommending all adults receive a one-time HCV test.”

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Glecaprevir/pibrentasvir (G/P) plus sofosbuvir and ribavirin can potentially treat patients who experienced previous virologic failure following G/P therapy.
HIV infection is associated with higher rates of hepatitis C replication.
An increasing number of patients with decompensated cirrhosis are receiving direct-acting antiviral treatment and attaining sustained virologic response of hepatitis C, however, their long-term outcomes are unclear.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.